Diagnostic Uses of Radiopharmaceuticals in Nuclear Medicine

Chapter

Keywords

Myocardial Perfusion Imaging Gamma Camera Medullary Thyroid Cancer Myocardial Uptake Scintillation Camera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Suggested Reading

  1. Anthony CP, Thibodeau GA. Textbook of Anatomy and Physiology. St. Louis: Mosby; 1979.Google Scholar
  2. Arnold RW, Subramanian G, McAfee JG, et al. Comparison of 99mTc complexes for renal imaging. J Nucl Med. 1975; 16:357.PubMedGoogle Scholar
  3. Atkins HL, Budinger TF, Lebowitz E, et al. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J Nucl Med. 1977; 18:133.PubMedGoogle Scholar
  4. Barrio JR, Huang SC, Melega WP, et al. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res. 1990; 27:487.CrossRefPubMedGoogle Scholar
  5. Berman DS, Kiat HS, Van Train KF, et al. Myocardial perfusion imaging with technetium-99m-sestamibi: comparative analysis of imaging protocols. J Nucl Med. 1994; 35:681.PubMedGoogle Scholar
  6. Delbeke D, Martin WH, Patton JA, et al., eds. Practical FDG Imaging. A Teaching File. New York: Springer Verlag; 2002.Google Scholar
  7. Dienel GA, Cruz NF, Sokoloff F. Metabolites of 2-deoxy-[14C]-glucose in plasma and brain: influence on rate of glucose utilization determined with deoxyglucose method in rat brain. J Cereb Blood Flow Metab. 1993; 13:315.PubMedGoogle Scholar
  8. Dilsizian V, Rocco TP, Freedman NMT, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium and stress-redistribution imaging. N Engl J Med. 1990; 323:141.PubMedCrossRefGoogle Scholar
  9. Early PJ, Sodee DB, eds. Principles and Practice of Nuclear Medicine. 2nd ed. St. Louis: Mosby; 1995.Google Scholar
  10. Freeman LM, ed. Freeman and Johnson’s Clinical Radionuclide Imaging. 3rd ed. New York: Grune & Stratton; 1984.Google Scholar
  11. Gould KL, Yoshida K, Hess MJ, et al. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med. 1991; 32:1.PubMedGoogle Scholar
  12. Harbert J, Eckelman WC, Neumann RD, eds. Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical; 1996.Google Scholar
  13. Hauser W, Atkins HL, Nelson KG, et al. Technetium-99m-DTPA: a new radiopharmaceutical for brain and kidney imaging. Radiology. 1970; 94:679.PubMedGoogle Scholar
  14. Henkin RE, Boles MA, Dillehay GL, et al., eds. Nuclear Medicine. St Louis: Mosby; 1996.Google Scholar
  15. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)-phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993; 34:30.PubMedGoogle Scholar
  16. Johnson LL, Seldin DW. Clinical experience with technetium-99m teboroxime, a neutral, lipophilic myocardial perfusion imaging agent. Am J Cardiol. 1990; 66: 63E.CrossRefPubMedGoogle Scholar
  17. Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial Tl-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol. 1988; 12(6):1456.PubMedCrossRefGoogle Scholar
  18. Kuhl DE, Barrio JR, Huang SC, et al. Quantifying local cerebral blood flow by N-isopropyl-p-123I-iodoamphetamine (IMP) tomography. J Nucl Med. 1982; 236:196.Google Scholar
  19. Leveille J, Demonceau G, DeRoo M, et al. Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans. J Nucl Med. 1989; 30:1902.PubMedGoogle Scholar
  20. Maisey MN, Britton KE, Collier BD. Clinical Nuclear Medicine. 3rd ed. London: Chapman & Hall; 1998.Google Scholar
  21. McAfee JG, Grossman ZD, Gagne G, et al. Comparison of renal extraction efficiencies for radioactive agents in the normal dog. J Nucl Med. 1981; 22:333.PubMedGoogle Scholar
  22. Mejia AA, Nakamura T, Masatoshi I, et al. Estimation of absorbed dose in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991; 32:699.PubMedGoogle Scholar
  23. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging. 4th ed. Philadelphia: Saunders; 1998.Google Scholar
  24. Murray IPC, Ell PJ. Nuclear Medicine in Clinical Diagnosis and Treatment. 2nd ed. Edinburgh: Churchill Livingstone; 1998.Google Scholar
  25. Narra RK, Nunn AD, Kuczynski, et al. A neutral technetium-99m complex for myocardial imaging. J Nucl Med. 1989; 30:1830.PubMedGoogle Scholar
  26. Phelps ME, Hoffman EJ, Selin C, et al. Investigation of F-18-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978; 19:1311.PubMedGoogle Scholar
  27. Ruhlmann J, Oehr P, Biersack HJ, eds. PET in Oncology. Basics and Clinical Applications. Heidelberg: Springer Verlag; 1999.Google Scholar
  28. Saha GB, Go RT, MacIntyre WJ, et al. Use of 82Sr/82Rb generator in clinical PET studies. Nucl Med Biol. 1990; 17:763.Google Scholar
  29. Saha GB, MacIntyre WJ, Brunken RC, et al. Present assessment of myocardial viability by nuclear imaging. Semin Nucl Med. 1996; 26:315.PubMedGoogle Scholar
  30. Sandler MP, Coleman RE, Walkers FJT, et al., eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore: Williams and Wilkins; 1996.Google Scholar
  31. Sapirstein LA, Vigt DG, Mandel MJ, et al. Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol. 1955; 181:330.PubMedGoogle Scholar
  32. Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981; 63:1259.PubMedGoogle Scholar
  33. Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HMPAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med. 1986; 27:171.PubMedGoogle Scholar
  34. Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987; 28:1625.PubMedGoogle Scholar
  35. Skehan SJ, White JF, Evans JW, et al. Mechanism of accumulation of 99mTc-sulesomab in inflammation. J Nucl Med. 2003; 44:11.PubMedGoogle Scholar
  36. Subramanian G, McAfee JG, Blair RJ, et al. Technetium 99m methylene diphosphonate—a superior agent for skeletal imaging; comparison with other technetium complexes. J Nucl Med. 1975; 16:744.PubMedGoogle Scholar
  37. Taylor A Jr, Eshima D, Christian PE, et al. Technetium-99m kit formulation; preliminary results in normal volunteers and patients with renal failure. J Nucl Med. 1988; 29:616.PubMedGoogle Scholar
  38. Taylor A Jr, Eshima D, Fritzberg AR, et al. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986; 27:795.PubMedGoogle Scholar
  39. Vallabhajosula S, Zimmerman RE, Pickard M, et al. Technetium-99m ECD: a new brain imaging agent. In vivo kinetics and biodistribution studies in normal human studies. J Nucl Med. 1989; 30:599.PubMedGoogle Scholar
  40. Vanzetto G, Fagret D, Pasqualini R, et al. Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTc-N-NOET in healthy volunteers. J Nucl Med. 2000; 41:141.PubMedGoogle Scholar
  41. Virkamaki A, Rissanen E, Hamalainen S. Incorporation of [3-sup3H]glucose and 2-[1-sup14C]deoxyglucose into glycogen in heart and skeletal muscle in vivo: Implications for the quantitation of tissue glucose uptake. Diabetes. 1997; 46:1106.PubMedGoogle Scholar
  42. Wackers FJT, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxy-isobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30:301.PubMedGoogle Scholar
  43. Wagner HN, Jr, Szabo Z, Buchanan JW. Principles of Nuclear Medicine. 2nd ed. Philadelphia: Saunders; 1995.Google Scholar
  44. Weiner RE. The mechanism of 67Ga localization in malignant disease. Nucl Med Biol. 1996; 23:745.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2004

Personalised recommendations